^
No biomarker
Osteosarcoma
doxorubicin hydrochloride
Sensitive: A1 - Approval
No biomarker
Osteosarcoma
ADX-2191
Sensitive: A1 - Approval
No biomarker
Osteosarcoma
regorafenib
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
gemcitabine + docetaxel + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cyclophosphamide oral + regorafenib
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
sorafenib + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide oral + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + cyclophosphamide oral
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cyclophosphamide oral + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
gemcitabine + docetaxel + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
carboplatin + ifosfamide
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cisplatin + ifosfamide + methotrexate + SGN-15
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cisplatin + ifosfamide + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
ifosfamide + etoposide oral + methotrexate
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
sorafenib + everolimus
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cyclophosphamide oral + topotecan
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cabozantinib tablet
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
sorafenib
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
ifosfamide
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cisplatin + SGN-15 + methotrexate IV
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
cisplatin + SGN-15
Sensitive: A2 - Guideline
TMB-H
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
MAP
Sensitive: A2 - Guideline
No biomarker
Osteosarcoma
methotrexate
Sensitive: A2 - Guideline
NTRK2 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
ERCC1 K504Q
Osteosarcoma
cisplatin
Resistant: C3 – Early Trials
XPC K939G
Osteosarcoma
cisplatin
Sensitive: C3 – Early Trials
ERCC2 K751G
Osteosarcoma
cisplatin
Resistant: C3 – Early Trials
ERCC1 N118N
Osteosarcoma
cisplatin
Resistant: C3 – Early Trials
ERCC2 D312N
Osteosarcoma
cisplatin
Resistant: C3 – Early Trials
ABCG2 overexpression
Osteosarcoma
MAP
Resistant: C3 – Early Trials
PGP overexpression
Osteosarcoma
ifosfamide + mifamurtide
Sensitive: C3 – Early Trials
TAF15-CHN1 translocation
Osteosarcoma
SP2577
Sensitive: C3 – Early Trials
KANK1-NTRK2 fusion
Osteosarcoma
crizotinib
Sensitive: C3 – Early Trials
CDK4 amplification
Osteosarcoma
palbociclib + lenvatinib
Sensitive: C3 – Early Trials
EGFR overexpression
Osteosarcoma
gemcitabine
Resistant: D – Preclinical
IGF1R expression
Osteosarcoma
IGF-1R inhibitor
Sensitive: D – Preclinical
RB1 positive
Osteosarcoma
palbociclib
Sensitive: D – Preclinical
KDM1A overexpression
Osteosarcoma
SP2577
Sensitive: D – Preclinical
MALAT1 overexpression
Osteosarcoma
doxorubicin hydrochloride
Resistant: D – Preclinical